STAT+: Biopharma industry at odds over impact of Treasury’s new China rule

An exemption for a common kind of biopharma deal is at the heart of disagreements over the proposal.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet